View of What can we expect from venetoclax + azacitidine (Ven + Aza) treatment in patients with acute myeloid leukemia (AML): Results from the VIALE-A study and post-hoc analyses.

Return to Issue Details What can we expect from venetoclax + azacitidine (Ven + Aza) treatment in patients with acute myeloid leukemia (AML): Results from the VIALE-A study and post-hoc analyses. Download Download PDF